Back
Results - Announcements
Concord Biotech Ltd consolidated sales down 21.03% on year in Q2FY2026, net profit tumbled by 34.78%
31-Jul-2026, 08:32
Concord Biotech Ltd share price ticked higher by 0.23% to Rs 1333.2. The Company's net profit plunged by 34.78% to Rs 57.7 crore, while revenue from operations nosedived 21.03% to Rs 257.49 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 23.86 lakh crore, easing 6%. It has marginally improved by 2.79% over last one week and spiked sharply by 15.59% in last one month while the market capitalization of Concord Biotech Ltd has gained 13.75% and 24.57% in the same period respectively. Profit before tax (PBT) of Concord Biotech Ltd stood at Rs 78.34 crore in Q2 FY26, jumping 33.39% year-on-year, and plunging by 31.33% quarter-on-quarter. EBITDA came in at Rs 70 crore, rallying 45.75% YoY and nosediving by 32.59% sequentially. Total expenses fell by 14.92% to Rs 193.21 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 69.85 crore, slightly declining by 0.98% YoY, while employee benefits expense was at Rs 43.64 crore, dropping 8.65% YoY. For the TTM ended FY26, revenue from operations fell 12.10% to Rs 1054.89 crore, while net profit tanked by 30.25% to Rs 259.23 crore, compared to previous TTM. EBITDA jumped by 48097% to Rs 315.04 crore, and PBT collapsed by 30.31% to Rs 344.65 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 266.88 crore in FY26, as against Rs 244.52 crore in FY25. Concord Biotech Ltd crashed 26.39% in last one year, underperforming the benchmark BSE Sensex which has slipped by 4.36% during the same period.
Concord Biotech Ltd share price ticked higher by 0.23% to Rs 1333.2. The Company's net profit plunged by 34.78% to Rs 57.7 crore, while revenue from operations nosedived 21.03% to Rs 257.49 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 23.86 lakh crore, easing 6%. It has marginally improved by 2.79% over last one week and spiked sharply by 15.59% in last one month while the market capitalization of Concord Biotech Ltd has gained 13.75% and 24.57% in the same period respectively. Profit before tax (PBT) of Concord Biotech Ltd stood at Rs 78.34 crore in Q2 FY26, jumping 33.39% year-on-year, and plunging by 31.33% quarter-on-quarter. EBITDA came in at Rs 70 crore, rallying 45.75% YoY and nosediving by 32.59% sequentially. Total expenses fell by 14.92% to Rs 193.21 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 69.85 crore, slightly declining by 0.98% YoY, while employee benefits expense was at Rs 43.64 crore, dropping 8.65% YoY. For the TTM ended FY26, revenue from operations fell 12.10% to Rs 1054.89 crore, while net profit tanked by 30.25% to Rs 259.23 crore, compared to previous TTM. EBITDA jumped by 48097% to Rs 315.04 crore, and PBT collapsed by 30.31% to Rs 344.65 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 266.88 crore in FY26, as against Rs 244.52 crore in FY25. Concord Biotech Ltd crashed 26.39% in last one year, underperforming the benchmark BSE Sensex which has slipped by 4.36% during the same period.